登录 注册 会员服务 联系我们

Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer

  • Published:2022-10-21 Issue:6 Volume:40 Page:1315-1321
  • ISSN:0167-6997
  • Container-title:Investigational New Drugs
  • language:en
  • Short-container-title:Invest New Drugs

Author:

Sumi Toshiyuki,Sekikawa Motoki,Nagahisa Yuta,Matsuura Keigo,Shijubou Naoki,Kamada Koki,Watanabe Hiroki,Yamada Yuichi,Tanaka Yusuke,Chiba Hirofumi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Reference19 articles.

1. Borghaei H, Gettinger S, Vokes EE et al (2021) Five-year outcomes from the randomized, Phase III trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol 39:723–733. https://doi.org/10.1200/JCO.20.01605

2. Paz-Ares LG, Ramalingam SS, Ciuleanu TE et al (2022) First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol 17:289–308. https://doi.org/10.1016/j.jtho.2021.09.010

3. Reck M, Ciuleanu TE, Cobo M et al (2021) Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open volume 6, Issue 5, October 2021, 100273]. ESMO Open 6:100345. https://doi.org/10.1016/j.esmoop.2021.100345. Erratum for (2021) ESMO Open 6. http://www.ncbi.nlm.nih.gov/pubmed/100273

4. Shankar B, Zhang J, Naqash AR et al (2020) Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol 6:1952–1956. https://doi.org/10.1001/jamaoncol.2020.5012

5. Wang W, Gu X, Wang L et al (2022) The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: A multicenter retrospective study. Cancer Immunol Immunother 71:1693–1703. https://doi.org/10.1007/s00262-021-03115-y

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3